|
St. Jude Occluder Misses Endpoint, Company Gets Predicted Form 483
St. Jude Medical announced Thursday that the company’s Amplatzer PFO Occluder has missed its primary endpoint in the RESPECT trial to evaluate the device’s success at reducing recurrent stroke risk.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives